The key novel findings of this work are that 5-substituted pyrazinoylguanidine-type NHE1 inhibitors accumulate in cancer cells grown under 3D conditions and exert potent, multifaceted cytotoxic effects unrelated to NHE1 inhibition. Here, SLC9A1 is linked to cancer.